Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Cefazolin 3g in Obese Surgical Patients
NCT05205486Phase 1Completed
- Sponsor
- B. Braun
- Start
- Apr 2022
- Primary completion
- Jul 2023
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cefazolin in surgical site infection (SSI), sponsored by B. Braun. Primary endpoint: Cefazolin Plasma Concentration Following Infusion at 8 hours. Started Apr 2022; status: completed.
02
Drugs
cefazolin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT05205486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205486.